🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Treatment of Early Supraglottic Squamous Cell Carcinoma With Advance Technologies

Recruitingn/aAges 18 Years - anyAllCentre Hospitalier Universitaire UCLouvain Namur
NCT05611515 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

In this project, the investigators will realize an observational, prospective, multicentric and international clinical trial, to objectively compare patients with SSCC according to 3 arms of treatment: * Arm 1: Radiotherapy ± chemotherapy * Arm 2: Trans-oral Laser Microsurgery (TLM) * Arm 3: Trans-oral Robotic Surgery (TORS) The main goal is to evaluate the efficacy of each treatment with four classes of outcomes: * The quality of life (QoL) before and after each treatment option, using validated questionnaires * Oncological outcomes * Functional outcomes * Economical Resources The population will include cT1-T2 /cN0-N1/M0 supraglottic squamous cell carcinoma. The primary outcome is a Clinical Dysphagia QoL evaluation assessed by the MD Anderson Dysphagia questionnaire. Secondary outcomes include others QoL evaluation, oncological and functional measures and cost parameters. The sam

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Diagnosis of SSCC (with histological confirmation) * cT1-T2 / cN0-N1/ M0 according to 8th TNM classification (UICC/AJCC) * WITH a Multidisciplinary Tumor Board decision according to the NCCN or European guidelines * Diagnostic imaging (Head and neck and pulmonary CT or PET/CT, +/- IRM if needed) realized within 1 month before the study inclusion * ≥ 18 years old and able to provide an informed consent * ECOG/WHO performance status ≤ 2 Exclusion Criteria: * \- Previous radiotherapy +/- chemotherapy treatment of the head and neck region * Previous history of head and neck cancer within 5 years * Prior invasive malignant disease unless disease-free for at least 5 years or more, with exception of non-melanoma skin cancer * Non-supraglottic or unknown primary site * Clinical and radiological signs of nodal extracapsular extension * Significant trismus (maximum inter-incisal opening ≤ 35 mm) * Pre-existing dysphagia not related to the cancer or the biopsy (from neurological disorders for example) * Unable or unwilling to complete Quality of Life questionnaires * Serious medical comorbidities or contraindication for surgery and/or radiation * Pregnancy and lactation
💊

What it tests

  • TORS
📍

Where

1 site
CHU UCL Namur
Yvoir, Belgium
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy